GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Pre-Tax Income

INKT (MiNK Therapeutics) Pre-Tax Income : $-17.09 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. MiNK Therapeutics's pretax income for the three months ended in Jun. 2024 was $-2.70 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was $-17.09 Mil. MiNK Therapeutics's pretax margin was %.

During the past 5 years, MiNK Therapeutics's highest Pretax Margin was -3449.57%. The lowest was -3449.57%. And the median was -3449.57%.


MiNK Therapeutics Pre-Tax Income Historical Data

The historical data trend for MiNK Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Pre-Tax Income Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
-23.80 -16.24 -30.21 -27.99 -22.46

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.20 -5.12 -5.46 -3.81 -2.70

Competitive Comparison of MiNK Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, MiNK Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's Pre-Tax Income falls into.



MiNK Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

MiNK Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-22.921+0+0+0.463+0
=-22.46

MiNK Therapeutics's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-3.071+0.331+0+0.038+4.4408920985006E-16
=-2.70

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiNK Therapeutics  (NAS:INKT) Pre-Tax Income Explanation

MiNK Therapeutics's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-2.702/0
=%

During the past 5 years, MiNK Therapeutics's highest Pretax Margin was -3449.57%. The lowest was -3449.57%. And the median was -3449.57%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiNK Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010